Myelodysplastic Syndromes |
Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA
Correspondence: Peter D. Aplan, Navy 8, Room 5101 8901 Wisconsin Ave, Bethesda MD 20889 USA.E-mail:aplanp{at}mail.nih.gov
Expression of a NUP98-HOXD13 (NHD13) fusion gene, initially identified in a patient with myelodysplastic syndrome, leads to a highly penetrant myelodysplastic syndrome in mice that recapitulates all of the key features of the human disease. Expansion of undifferentiated lineage negative (linneg) hematopoietic precursors that express NHD13 was markedly inhibited (30-fold) in vitro. Decreased expansion was accompanied by decreased production of terminally differentiated cells, indicating impaired differentiation of NHD13 precursors. Rather than differentiate, the majority (80%) of NHD13 linneg precursors underwent apoptotic cell death when induced to differentiate. These findings demonstrate that NHD13 linneg cells provide a tractable in vitro system for studies of myelodysplastic syndrome.
Key words: myelodysplastic syndromes, mouse model, NUP98, HOXD13, apoptosis.
This article has been cited by other articles:
![]() |
M. Fontenay and E. Gyan Apoptotic pathways to death in myelodysplastic syndromes Haematologica, September 1, 2008; 93(9): 1288 - 1292. [Full Text] [PDF] |
||||